TP53 and B-cell chronic lymphocytic leukemia: Furthermore, we were able to recapitulate this combination of events (del(11q) TP53MUT) in in vitro CLL models using the CRISPR/Cas9 editing system, showing that these cells have an in vivo clonal advantage over del(11q) cells without TP53 alterations, offering a biological insight into the cooperation of these alterations in CLL progression and relapse.